An investigational once-daily pill added to optimised insulin therapy has been shown to reduce HbA1c among adults with Type 1 diabetes during a 12-week trial when compared with a placebo alongside insulin.
The pill – a novel liver-selective glucokinase activator known as TTP399 – was associated with a placebo-subtracted HbA1c reduction of 0.32% at 12 weeks when compared with placebo.
“This may be the first adjunctive therapy that can help people improve their glycaemic control without increasing the risk for hypoglycaemia,” Carmen Valcarce, Chief Scientific Officer of vTv Therapeutics, said. “Fear of hypoglycaemia is what keeps people from achieving their target goals. That is the major take-home message.”
Research for adjunctive, oral pharmacotherapies to treat type 1 diabetes has been limited by hypoglycaemia and diabetic ketoacidosis (DKA).
TTP399 selectively activates glucokinase, a key regulator of glucose metabolism, in the liver. This activation has been shown to increase glucose utilisation, which in turn, lowers blood glucose. Researchers said the drug was well tolerated, with no DKA in either treatment group and no severe hypoglycaemia in the treated group and one incident in the placebo group.
The findings from the phase 2 Simplici-T1 trial were presented at the virtual European Association for the Study of Diabetes (EASD) conference in September.